This, added to the evidence of a strong correlation between Lf secretion from activated microglia and Aβ production, led to the consideration of the inhibition of the interaction between Lf and APP as a potential therapeutic target for AD treatment [55]. The gene discussed is APP; the disease is Alzheimer disease.